Recently reported clinical data indicated that 7–33% of responders in CAR-19 T-cell trials for B-cell acute lymphoblastic lymphoma (B-ALL) relapsed because of the loss of cell-surface CD19 (32). Here, CD19 is linked to acute lymphoblastic leukemia.